Trastuzumab Deruxtecan Effective For HR-Positive, HER2-Low Breast Cancer Treatment After Endocrine Therapy
At the American Society of Clinical Oncology (ASCO) 2024 annual meeting in Chicago, Illinois, researchers presented study results from DESTINY-Breast06 (DB-06) (NCT04494425) that found trastuzumab deruxtecan (T-DXd) reduces cancer growth for patients with …